Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lactiplantibacillus plantarum DAD-13 in ICU Sepsis Patients
NCT07072871Completed
- Sponsor
- Royal Medicalink Pharmalab
- Start
- Feb 2025
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Randomised, double-blind trial in sepsis (2 arms), sponsored by Royal Medicalink Pharmalab. Primary endpoint: Procalcitonin at 4 days. Started Feb 2025; status: completed.
02
Conditions
sepsis
Beyond the preview
Go deeper on NCT07072871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072871.